BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis

BIT:1BMY • US1101221083

51.02 EUR
-0.02 (-0.04%)
Last: Feb 12, 2026, 07:00 PM
Fundamental Rating

4

Taking everything into account, 1BMY scores 4 out of 10 in our fundamental rating. 1BMY was compared to 55 industry peers in the Pharmaceuticals industry. 1BMY has an average financial health and profitability rating. 1BMY is valued quite cheap, but it does not seem to be growing. Finally 1BMY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • 1BMY had positive earnings in the past year.
  • In the past year 1BMY had a positive cash flow from operations.
  • Of the past 5 years 1BMY 4 years were profitable.
  • Of the past 5 years 1BMY 4 years had a positive operating cash flow.
1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • 1BMY has a Return On Assets (6.23%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of 32.55%, 1BMY is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
  • 1BMY's Return On Invested Capital of 17.49% is fine compared to the rest of the industry. 1BMY outperforms 74.55% of its industry peers.
  • 1BMY had an Average Return On Invested Capital over the past 3 years of 11.67%. This is below the industry average of 14.21%.
  • The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(17.49%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROIC 17.49%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1BMY.MI Yearly ROA, ROE, ROIC1BMY.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • The Profit Margin of 1BMY (12.57%) is comparable to the rest of the industry.
  • 1BMY has a better Operating Margin (33.51%) than 81.82% of its industry peers.
  • 1BMY's Operating Margin has declined in the last couple of years.
  • The Gross Margin of 1BMY (73.15%) is comparable to the rest of the industry.
  • 1BMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
1BMY.MI Yearly Profit, Operating, Gross Margins1BMY.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1BMY is creating value.
  • There is no outstanding debt for 1BMY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1BMY.MI Yearly Shares Outstanding1BMY.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
1BMY.MI Yearly Total Debt VS Total Assets1BMY.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 2.33 indicates that 1BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.33, 1BMY is in line with its industry, outperforming 41.82% of the companies in the same industry.
  • 1BMY has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as 1BMY would need 3.20 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 3.20, 1BMY is doing good in the industry, outperforming 67.27% of the companies in the same industry.
  • A Debt/Equity ratio of 2.41 is on the high side and indicates that 1BMY has dependencies on debt financing.
  • 1BMY's Debt to Equity ratio of 2.41 is on the low side compared to the rest of the industry. 1BMY is outperformed by 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Altman-Z 2.33
ROIC/WACC2.05
WACC8.55%
1BMY.MI Yearly LT Debt VS Equity VS FCF1BMY.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.3 Liquidity

  • 1BMY has a Current Ratio of 1.27. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
  • 1BMY has a worse Current ratio (1.27) than 60.00% of its industry peers.
  • A Quick Ratio of 1.17 indicates that 1BMY should not have too much problems paying its short term obligations.
  • 1BMY has a better Quick ratio (1.17) than 69.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.17
1BMY.MI Yearly Current Assets VS Current Liabilites1BMY.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • The Earnings Per Share has been decreasing by -0.92% on average over the past years.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.16% on average over the next years.
  • 1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.36% yearly.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
1BMY.MI Yearly Revenue VS Estimates1BMY.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
1BMY.MI Yearly EPS VS Estimates1BMY.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.85 indicates a reasonable valuation of 1BMY.
  • 90.91% of the companies in the same industry are more expensive than 1BMY, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of 1BMY to the average of the S&P500 Index (27.97), we can say 1BMY is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 9.96, the valuation of 1BMY can be described as very reasonable.
  • 1BMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BMY is cheaper than 85.45% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.96. 1BMY is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.85
Fwd PE 9.96
1BMY.MI Price Earnings VS Forward Price Earnings1BMY.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 1BMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BMY is cheaper than 92.73% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1BMY indicates a rather cheap valuation: 1BMY is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.06
EV/EBITDA 7.37
1BMY.MI Per share data1BMY.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • 1BMY's earnings are expected to decrease with -3.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 4.21%, 1BMY is a good candidate for dividend investing.
  • 1BMY's Dividend Yield is rather good when compared to the industry average which is at 1.92. 1BMY pays more dividend than 85.45% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, 1BMY pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.21%

5.2 History

  • The dividend of 1BMY is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1BMY pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
  • 1BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
1BMY.MI Yearly Income VS Free CF VS Dividend1BMY.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
1BMY.MI Dividend Payout.1BMY.MI Dividend Payout, showing the Payout Ratio.1BMY.MI Dividend Payout.PayoutRetained Earnings

BRISTOL-MYERS SQUIBB CO

BIT:1BMY (2/12/2026, 7:00:00 PM)

51.02

-0.02 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap103.86B
Revenue(TTM)N/A
Net Income(TTM)6.04B
Analysts70.59
Price Target48.75 (-4.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.21%
Yearly Dividend2.04
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)7.65%
PT rev (3m)9.84%
EPS NQ rev (1m)-32.03%
EPS NQ rev (3m)-28.42%
EPS NY rev (1m)-8.25%
EPS NY rev (3m)-7.94%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)1.43%
Valuation
Industry RankSector Rank
PE 9.85
Fwd PE 9.96
P/S 2.57
P/FCF 8.06
P/OCF 7.42
P/B 6.65
P/tB N/A
EV/EBITDA 7.37
EPS(TTM)5.18
EY10.15%
EPS(NY)5.12
Fwd EY10.05%
FCF(TTM)6.33
FCFY12.41%
OCF(TTM)6.88
OCFY13.48%
SpS19.87
BVpS7.67
TBVpS-9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.91
Profitability
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROCE 23.41%
ROIC 17.49%
ROICexc 22.99%
ROICexgc 117.18%
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
FCFM 31.86%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Debt/EBITDA 2.13
Cap/Depr 26.84%
Cap/Sales 2.75%
Interest Coverage 7.66
Cash Conversion 79.11%
Profit Quality 253.39%
Current Ratio 1.27
Quick Ratio 1.17
Altman-Z 2.33
F-Score6
WACC8.55%
ROIC/WACC2.05
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year220.11%
EBIT Next 3Y49.61%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%

BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ

Can you provide the ChartMill fundamental rating for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a fundamental rating of 4 / 10 to 1BMY.MI.


Can you provide the valuation status for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (1BMY.MI). This can be considered as Undervalued.


Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?

BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a profitability rating of 5 / 10.


Can you provide the financial health for 1BMY stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 4 / 10.


Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?

The dividend rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 7 / 10 and the dividend payout ratio is 82.81%.